The Washington Post, a Pulitzer Prize-winning publication with a global readership of millions, featured Prenosis in a detailed profile exploring its groundbreaking FDA-authorized AI diagnostic tool for sepsis. CEO Bobby Reddy, Jr. shares how the Sepsis ImmunoScore™ is revolutionizing patient care by tailoring treatment to individual biology.
Bobby Reddy Jr. roamed a hospital as he built his start-up, observing how patient care began with a diagnosis and followed a set protocol. The electrical engineer thought he knew a better way: an artificial intelligence tool that would individualize treatment.
Now, the Food and Drug Administration has greenlighted such a test developed by Reddy’s company, Chicago-based Prenosis, to predict the risk of sepsis — a complex condition that contributes to at least 350,000 deaths a year in the United States. It is the first algorithmic, AI-driven diagnostic tool for sepsis to receive the FDA’s go-ahead, the company said in a statement Wednesday.
“In hospitals and emergency departments, we are still relying on one-size-fits-all, when instead we should be treating each person based on their individual biology,” Reddy, the company’s CEO, said in an interview.
Sepsis occurs when a patient’s immune system tries to fight an infection and ends up attacking the body’s own organs. Managing sepsis is a priority among federal health agencies including the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services.
“Sepsis is a serious and sometimes deadly complication,” Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, said in a statement. “Technologies developed to help prevent this condition have the potential to provide a significant benefit to patients.”
To build its test, Prenosis acquired more than 100,000 blood samples along with clinical data on hospital patients, and trained its algorithm to recognize the health measures most associated with developing sepsis. The company narrowed its test to 22 parameters, including blood-based measures and other vital signs such as temperature and heart rate. The diagnostic tool now produces a snapshot that classifies a patient’s risk of sepsis in four categories, from low to very high.
Read the rest of the profile in the Washington Post.